TGTX

TGTX

USD

TG Therapeutics Inc. Common Stock

$33.845+0.775 (2.344%)

即時價格

Healthcare
生物科技
美國

價格圖表

Loading Chart...

關鍵指標

市場指標
公司基本面
交易統計

市場指標

開盤

$33.070

最高

$34.325

最低

$32.772

交易量

1.47M

公司基本面

市值

5.4B

行業

生物科技

國家

United States

交易統計

平均交易量

2.11M

交易所

NCM

貨幣

USD

52週範圍

最低 $23.6當前 $33.845最高 $46.48

相關新聞

Analyst Upgrades

JP Morgan Maintains Overweight on TG Therapeutics, Raises Price Target to $49

JP Morgan analyst Eric Joseph maintains TG Therapeutics with a Overweight and raises the price target from $46 to $49.

查看更多
JP Morgan Maintains Overweight on TG Therapeutics, Raises Price Target to $49
GlobeNewswire

TG Therapeutics Reports Third Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance

Third quarter 2025 total revenue of $161.7 million, including BRIUMVI U.S. net revenue of $152.9 million Raises full year 2025 global revenue target to $600 million, and raises full year BRIUMVI U.S. net revenue target

查看更多
TG Therapeutics Reports Third Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance
GlobeNewswire

TG Therapeutics to Host Conference Call on Third Quarter 2025 Financial Results and Business Update

NEW YORK, Oct. 31, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that a conference call will be held, Monday, November 3, 2025, at 8:30 AM ET to discuss results for the third quarter of

查看更多
TG Therapeutics to Host Conference Call on Third Quarter 2025 Financial Results and Business Update
GlobeNewswire

TG Therapeutics Completes Enrollment in the Phase 3 ENHANCE Trial Evaluating its New Simplified Dosing Schedule for BRIUMVI

NEW YORK, Oct. 28, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), announced today that enrollment has completed in the randomized cohort of the Phase 3 ENHANCE trial evaluating a consolidated Day 1 and

查看更多
TG Therapeutics Completes Enrollment in the Phase 3 ENHANCE Trial Evaluating its New Simplified Dosing Schedule for BRIUMVI